Chemotherapy Before Surgery for Lung Cancer
Author Information
Author(s): Date H, Kiura K, Ueoka H, Tabata M, Aoe M, Andou A, Shibayama T, Shimizu N
Primary Institution: Okayama University School of Medicine
Hypothesis
Is surgical resection after induction chemotherapy with cisplatin and irinotecan feasible and does it improve treatment outcomes for patients with pathological N2 non-small cell lung cancer?
Conclusion
Surgical resection after induction chemotherapy with cisplatin and irinotecan is feasible and associated with low morbidity and high resectability.
Supporting Evidence
- The objective response rate after induction chemotherapy was 73%.
- Complete resection was achieved in 11 out of 15 patients (73%).
- The 5-year survival rate was 40% for all patients and 55% for those who underwent complete resection.
Takeaway
Doctors gave special medicine to patients with lung cancer before surgery to see if it helped them get better. Most patients did well and many could have their cancer removed.
Methodology
Patients received two cycles of chemotherapy followed by surgical resection, with evaluations for response and toxicity.
Limitations
The study included a small sample size of only 15 patients.
Participant Demographics
The mean age was 60 years, with 13 men and 2 women; histological types included adenocarcinoma, squamous, large-cell, and adeno-squamous.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website